Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Vanda Pharmaceuticals Inc (NASDAQ:VNDA)

10.70
Delayed Data
As of 4:00pm ET
 -0.46 / -4.12%
Today’s Change
6.91
Today|||52-Week Range
14.50
+14.93%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$481.6M

Company Description

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders. Its products portfolio includes HETLIOZ, Fanapt and Tradipitant, Trichostatin and AQW051. Vanda Pharmaceuticals was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Contact Information

Vanda Pharmaceuticals, Inc.
2200 Pennsylvania Avenue NW
Washington District Of Columbia 20037
P:(202) 734-3400
Investor Relations:
(202) 734-3428

Employees

Shareholders

Other institutional77.67%
Individual stakeholders42.88%
Mutual fund holders19.22%

Top Executives

Mihael Hristos PolymeropoulosPresident, Chief Executive Officer & Director
James Patrick KellyChief Financial Officer, Treasurer & Senior VP
Paolo BaroldiChief Medical Officer & Senior Vice President
Gian ReverberiChief Commercial Officer & Senior Vice President
Richard L. GulinoSecretary, General Counsel & Senior VP